137. Long GV et al (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients
with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of
a phase 3 study. Ann Oncol 28(7):1631–1639
138. Long GV et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated
melanoma. N Engl J Med 377(19):1813–1823
139. Ascierto PA et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase
3 trial. Lancet Oncol 17(9):1248–1260
140. Griffin M et al (2017) BRAF inhibitors: resistance and the promise of combination treatments
for melanoma. Oncotarget 8(44):78174–78192
141. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as
anticancer agents. Nat Rev Drug Discov 5:671
142. Anagnostopoulou V et al (2013) Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF)
receptors. Endocrinology 154:2446
143. WeiSz L, Efferth T (2012) Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol
1:38
144. Akinleye A et al (2013) Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
J Hematol Oncol 6:88
145. Fayard E et al (2011) Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling
pathway. In: Phosphoinositide 3-kinase in health and disease. Springer, New York, pp 31–56
146. Cance WG et al (2013) Disrupting the scaffold to improve focal adhesion kinase–targeted
cancer therapeutics. Sci Signal 6:pe10
147. Ahmed K et al (2015) Targeting CK2 for cancer therapy using a nanomedicine approach. In:
Protein kinase CK2 cellular function in normal and disease states. Springer, New York, pp
299–315
148. Hilton JF, Shapiro GI (2014) Aurora kinase inhibition as an anticancer strategy. J Clin Oncol
32:57
149. Jones JA et al (2017) Efficacy and safety of idelalisib in combination with ofatumumab for
previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Lancet Haematol 4(3):e114–e126
150. Pandey R, Kapur R (2018) Kinase inhibitors in clinical practice: an expanding world. J Allergy
Clin Immunol 141(2):522–524
151. Shapiro GI et al (2015) First-in-human study of PF-05212384 (PKI-587), a small-molecule,
intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer
Res 21(8):1888–1895
152. Eriksson A et al (2015) Drug screen in patient cells suggests quinacrine to be repositioned for
treatment of acute myeloid leukemia. Blood Cancer J 5:e307
153. Haïk S et al (2014) Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, doubleblind, placebo-controlled trial. Lancet Neurol 13:150
154. Bedard PL et al (2014) Abstract CT205: a phase I dose-escalation study of trametinib (T) in
combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with
advanced solid tumors. Cancer Res 74:CT205
155. Dowsett M et al (2012) Phase II randomized study of pre-operative pf-04691502 plus letrozole
compared with letrozole (L) in patients with estrogen receptor-positive, HER2-negative early
breast cancer (BC). Ann Oncol 23:44
156. Powles T et al (2014) A randomized phase II study of GDC-0980 versus everolimus in
metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGFTT). J Clin Oncol 32(15_suppl):4525
157. Yu P et al (2014) Characterization of the activity of the PI3K/mTOR inhibitor XL765
(SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Mol Cancer Ther 13:1078
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical. . .
151
with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of
a phase 3 study. Ann Oncol 28(7):1631–1639
138. Long GV et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated
melanoma. N Engl J Med 377(19):1813–1823
139. Ascierto PA et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase
3 trial. Lancet Oncol 17(9):1248–1260
140. Griffin M et al (2017) BRAF inhibitors: resistance and the promise of combination treatments
for melanoma. Oncotarget 8(44):78174–78192
141. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as
anticancer agents. Nat Rev Drug Discov 5:671
142. Anagnostopoulou V et al (2013) Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF)
receptors. Endocrinology 154:2446
143. WeiSz L, Efferth T (2012) Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol
1:38
144. Akinleye A et al (2013) Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
J Hematol Oncol 6:88
145. Fayard E et al (2011) Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling
pathway. In: Phosphoinositide 3-kinase in health and disease. Springer, New York, pp 31–56
146. Cance WG et al (2013) Disrupting the scaffold to improve focal adhesion kinase–targeted
cancer therapeutics. Sci Signal 6:pe10
147. Ahmed K et al (2015) Targeting CK2 for cancer therapy using a nanomedicine approach. In:
Protein kinase CK2 cellular function in normal and disease states. Springer, New York, pp
299–315
148. Hilton JF, Shapiro GI (2014) Aurora kinase inhibition as an anticancer strategy. J Clin Oncol
32:57
149. Jones JA et al (2017) Efficacy and safety of idelalisib in combination with ofatumumab for
previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Lancet Haematol 4(3):e114–e126
150. Pandey R, Kapur R (2018) Kinase inhibitors in clinical practice: an expanding world. J Allergy
Clin Immunol 141(2):522–524
151. Shapiro GI et al (2015) First-in-human study of PF-05212384 (PKI-587), a small-molecule,
intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer
Res 21(8):1888–1895
152. Eriksson A et al (2015) Drug screen in patient cells suggests quinacrine to be repositioned for
treatment of acute myeloid leukemia. Blood Cancer J 5:e307
153. Haïk S et al (2014) Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, doubleblind, placebo-controlled trial. Lancet Neurol 13:150
154. Bedard PL et al (2014) Abstract CT205: a phase I dose-escalation study of trametinib (T) in
combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with
advanced solid tumors. Cancer Res 74:CT205
155. Dowsett M et al (2012) Phase II randomized study of pre-operative pf-04691502 plus letrozole
compared with letrozole (L) in patients with estrogen receptor-positive, HER2-negative early
breast cancer (BC). Ann Oncol 23:44
156. Powles T et al (2014) A randomized phase II study of GDC-0980 versus everolimus in
metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGFTT). J Clin Oncol 32(15_suppl):4525
157. Yu P et al (2014) Characterization of the activity of the PI3K/mTOR inhibitor XL765
(SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Mol Cancer Ther 13:1078
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical. . .
151